125 related articles for article (PubMed ID: 21278576)
1. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
Liu X; Tepper PG; Able SL
Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
[TBL] [Abstract][Full Text] [Related]
2. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
3. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.
Cui Z; Faries DE; Gelwicks S; Novick D; Liu X
J Med Econ; 2012; 15(1):134-44. PubMed ID: 22014076
[TBL] [Abstract][Full Text] [Related]
4. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
5. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder.
Liu X; Gelwicks S; Faries DE; Able SL
Int Clin Psychopharmacol; 2010 Nov; 25(6):315-22. PubMed ID: 20706125
[TBL] [Abstract][Full Text] [Related]
6. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine.
Zhao Y; Chen SY; Wu N; Fraser KA; Boulanger L
Pain Pract; 2011; 11(4):381-91. PubMed ID: 21199311
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness in pain-related outcomes and health care utilizations between veterans with major depressive disorder treated with duloxetine and other antidepressants: a retrospective propensity score-matched comparison.
Shi L; Liu J; Zhao Y
Pain Pract; 2012 Jun; 12(5):374-81. PubMed ID: 21951787
[TBL] [Abstract][Full Text] [Related]
8. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
9. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
Liu X; Cui Z; Niu L; Faries DE; Ball T; Johnstone B
Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study.
Shi L; Liu J; Campbell C; Zhao Y
Curr Med Res Opin; 2010 Dec; 26(12):2715-21. PubMed ID: 20973616
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
Wu N; Chen S; Boulanger L; Fraser K; Bledsoe SL; Zhao Y
J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
Cui Z; Faries DE; Shen W; Able SL; Novick D
J Med Econ; 2013; 16(5):623-32. PubMed ID: 23425292
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
Perahia DG; Quail D; Gandhi P; Walker DJ; Peveler RC
J Affect Disord; 2008 May; 108(1-2):33-41. PubMed ID: 17905442
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom.
Shi N; Cao Z; Durden E; Schacht A; Torres A; Happich M
J Med Econ; 2012; 15(4):672-80. PubMed ID: 22390770
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
[TBL] [Abstract][Full Text] [Related]
18. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
20. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
